Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 28 | 2025 | 155 | 13.290 |
Why?
|
| Quinolones | 17 | 2025 | 50 | 9.000 |
Why?
|
| Aminophenols | 18 | 2025 | 19 | 8.170 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 17 | 2024 | 39 | 5.740 |
Why?
|
| Benzodioxoles | 11 | 2025 | 43 | 4.860 |
Why?
|
| Indoles | 8 | 2025 | 278 | 3.870 |
Why?
|
| Pyrazoles | 8 | 2025 | 114 | 3.740 |
Why?
|
| Pyridines | 8 | 2025 | 133 | 3.050 |
Why?
|
| Pyrrolidines | 6 | 2025 | 69 | 1.920 |
Why?
|
| Epithelial Cells | 6 | 2024 | 215 | 1.760 |
Why?
|
| Tacrolimus | 2 | 2025 | 60 | 1.580 |
Why?
|
| Drug Combinations | 6 | 2025 | 134 | 1.570 |
Why?
|
| Nasal Mucosa | 3 | 2021 | 19 | 1.520 |
Why?
|
| Lung Transplantation | 2 | 2025 | 39 | 1.110 |
Why?
|
| Organoids | 3 | 2021 | 39 | 1.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 134 | 1.050 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2024 | 250 | 1.040 |
Why?
|
| Immunosuppressive Agents | 2 | 2025 | 243 | 0.970 |
Why?
|
| Feasibility Studies | 2 | 2024 | 402 | 0.960 |
Why?
|
| Mutation | 7 | 2023 | 1351 | 0.920 |
Why?
|
| Neonatal Screening | 1 | 2024 | 49 | 0.880 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 238 | 0.870 |
Why?
|
| Humans | 33 | 2025 | 52336 | 0.690 |
Why?
|
| Genetic Therapy | 1 | 2020 | 120 | 0.630 |
Why?
|
| Liver Transplantation | 1 | 2021 | 165 | 0.620 |
Why?
|
| Rhodospirillaceae | 1 | 2018 | 1 | 0.590 |
Why?
|
| Staphylococcal Infections | 2 | 2018 | 280 | 0.580 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 26 | 0.570 |
Why?
|
| Rifampin | 1 | 2018 | 63 | 0.570 |
Why?
|
| Adult | 11 | 2025 | 14139 | 0.510 |
Why?
|
| Quinolines | 3 | 2025 | 44 | 0.510 |
Why?
|
| Young Adult | 7 | 2025 | 4319 | 0.490 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 801 | 0.470 |
Why?
|
| Chromatography, Liquid | 3 | 2024 | 240 | 0.460 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1222 | 0.450 |
Why?
|
| Sweat | 2 | 2024 | 9 | 0.390 |
Why?
|
| Female | 12 | 2025 | 28105 | 0.380 |
Why?
|
| Ion Transport | 2 | 2021 | 15 | 0.370 |
Why?
|
| Male | 11 | 2025 | 26696 | 0.350 |
Why?
|
| Adolescent | 8 | 2025 | 6692 | 0.350 |
Why?
|
| Pilot Projects | 2 | 2024 | 719 | 0.330 |
Why?
|
| Child | 9 | 2025 | 7157 | 0.320 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2025 | 55 | 0.280 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 80 | 0.270 |
Why?
|
| Pyrroles | 2 | 2024 | 71 | 0.270 |
Why?
|
| Cell Line | 3 | 2024 | 1045 | 0.250 |
Why?
|
| Oxygen | 1 | 2008 | 336 | 0.240 |
Why?
|
| Respiratory Mucosa | 1 | 2024 | 10 | 0.230 |
Why?
|
| Chlorides | 2 | 2024 | 43 | 0.220 |
Why?
|
| Dietary Fats | 1 | 2024 | 130 | 0.220 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 1006 | 0.210 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2023 | 39 | 0.210 |
Why?
|
| Pharmacogenetics | 1 | 2023 | 50 | 0.200 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 237 | 0.200 |
Why?
|
| Body Composition | 1 | 2024 | 339 | 0.190 |
Why?
|
| Middle Aged | 4 | 2025 | 13014 | 0.190 |
Why?
|
| Drug Prescriptions | 1 | 2023 | 102 | 0.190 |
Why?
|
| Insurance, Health | 1 | 2023 | 131 | 0.190 |
Why?
|
| Forced Expiratory Volume | 2 | 2020 | 52 | 0.190 |
Why?
|
| Nose | 1 | 2021 | 33 | 0.180 |
Why?
|
| Genotype | 1 | 2023 | 569 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1377 | 0.170 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 395 | 0.160 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5407 | 0.160 |
Why?
|
| Quality of Life | 3 | 2023 | 868 | 0.160 |
Why?
|
| Prospective Studies | 1 | 2025 | 2428 | 0.150 |
Why?
|
| Asthma | 1 | 2023 | 316 | 0.150 |
Why?
|
| Amikacin | 1 | 2018 | 19 | 0.150 |
Why?
|
| Clindamycin | 1 | 2018 | 14 | 0.150 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2018 | 7 | 0.150 |
Why?
|
| Ciprofloxacin | 1 | 2018 | 21 | 0.150 |
Why?
|
| Phenotype | 2 | 2020 | 799 | 0.150 |
Why?
|
| Pseudomonas Infections | 1 | 2018 | 54 | 0.140 |
Why?
|
| Body Weight | 1 | 2020 | 522 | 0.140 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2018 | 45 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2017 | 15 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1201 | 0.140 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 78 | 0.140 |
Why?
|
| Virulence | 1 | 2018 | 167 | 0.140 |
Why?
|
| Particle Size | 1 | 2017 | 78 | 0.140 |
Why?
|
| Drug Interactions | 1 | 2018 | 205 | 0.140 |
Why?
|
| Biological Transport | 1 | 2017 | 158 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2018 | 76 | 0.140 |
Why?
|
| Nutritional Status | 1 | 2018 | 137 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2024 | 2826 | 0.130 |
Why?
|
| Telemedicine | 1 | 2023 | 493 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2018 | 133 | 0.130 |
Why?
|
| Cells, Cultured | 1 | 2020 | 1589 | 0.130 |
Why?
|
| United States | 2 | 2024 | 5182 | 0.120 |
Why?
|
| Risk Factors | 1 | 2024 | 3872 | 0.120 |
Why?
|
| Lung | 3 | 2023 | 502 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2025 | 6578 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2268 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 47 | 0.070 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 83 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2008 | 347 | 0.070 |
Why?
|
| Respiratory Function Tests | 1 | 2025 | 89 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2023 | 28 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 25 | 0.050 |
Why?
|
| Sarcoma, Ewing | 1 | 2003 | 28 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2003 | 61 | 0.050 |
Why?
|
| Smoke | 1 | 2023 | 18 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 741 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 1903 | 0.050 |
Why?
|
| Transaminases | 1 | 2022 | 11 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2003 | 359 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 140 | 0.050 |
Why?
|
| Mice | 2 | 2008 | 5965 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2003 | 574 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 56 | 0.040 |
Why?
|
| Respiratory System | 1 | 2018 | 28 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2020 | 222 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2018 | 77 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2022 | 1532 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 727 | 0.030 |
Why?
|
| Cross Infection | 1 | 2018 | 93 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2018 | 146 | 0.030 |
Why?
|
| Animals | 3 | 2008 | 13523 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 870 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 689 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1127 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 107 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2018 | 233 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 706 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 331 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 659 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 3684 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 4030 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 2004 | 34 | 0.010 |
Why?
|
| Biotinylation | 1 | 2004 | 28 | 0.010 |
Why?
|
| COS Cells | 1 | 2004 | 85 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 44 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 71 | 0.010 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2003 | 8 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 106 | 0.010 |
Why?
|
| Lymphokines | 1 | 2003 | 20 | 0.010 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2003 | 13 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 110 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 179 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2004 | 263 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 182 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 372 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 2004 | 114 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2003 | 113 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 141 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 245 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 583 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 2004 | 101 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 184 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 623 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 596 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 462 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2003 | 858 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 2957 | 0.010 |
Why?
|